Insight

Aug 27, 2024, 21:09

5 papers about lung cancer suggested by Stephen Liu

Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers on X:

Final analysis data and exploratory biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFRmutations: the WJOG9717L study

Authors: Hirotsugu Kenmotsu et al.

Stephen Liu

The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)

Authors: Kageaki Watanabe et al.

Stephen Liu

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

Authors: James Chih-Hsin Yang et al.

Stephen Liu

Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients with Metastatic Non-Squamous NSCLC

Authors: Shreya Bhatia, Matthew Lu, Spencer Lessans, Michael Libre, Heidi Chen, Wade Iams

Stephen Liu

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study

Authors: Marion Ferreira et al.

Stephen Liu

Follow Stephen Liu on X for more such content.

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.

Alexis Cortot Anne-Claire Toffart Aurélie Swalduz cancer Charles Ricordel Cheng-Ta Yang Clotilde Descarpentries Dae Ho Lee David Vicente Diana Chirovsky Eiji Iwama Eiki Ichihara Emmanuel de la Mora Jimenez Filippo de Marinis Franck Morin Gaëlle Jeannin Go Naka Gonzague De Chabot Gregory J. Riely Guillaume Herbreteau Heidi Chen Hideo Kunitoh Hidetoshi Hayashi Hirotaka Matsumoto Hirotsugu Kenmotsu Hubert Curcio James Chih-Hsin Yang Jeronimo Rodríguez Cid Jianying Zhou Jong-Seok Lee José Hureaux Judith Raimbourg Kageaki Watanabe Katsuhiko Naoki Kazuhiko Nakagawa Kazuhiro Usui Kazuko Sakai Kazuma Kishi Kazumi Nishino Kazuto Nishio Keisuke Kirita Keita Mori Ken Masuda Ki Hyeong Lee Kiyotaka Yoh Kohei Uemura Koichi Azuma Laurent Greillier Li Zhang Luc Odier M. Catherine Pietanza Marie Wislez Marion Ferreira Matthew Lu Maurice Pérol Michael Libre Niyati Bhagwati Nobuyuki Yamamoto OncoDaily Oncology Pascale Missy Pauline du Rusquec Ryo Koyama Ryo Toyozawa Saori Takata Satoru Miura Satoshi Takahashi Sébastien Couraud Shreya Bhatia Shu Tamano Shun Lu Shunichi Sugawara Shunsuke Teraoka Spencer Lessans Sylvie Friard Takako Inoue Terufumi Kato Toshiaki Takahashi Valérie Gounant Virginie Westeel Wade Iams Yasuhito Fujisaka Yasuto Yoneshima Yiwen Luo Yoko Tsukita Yoshiro Nakahara Yuki Sato Yukio Hosomi Yun Fan

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage